Europe PMC

Objectives This study aimed to evaluate the required test characteristics that a psoriatic arthritis (PsA) biomarker test would need to achieve to be considered cost-effective.Methods We adapted an existing Markov model to compare a hypothetical biomarker with current practice. The model followed a patient cohort aged 45 years with moderate psoriasis (PsO) in which PsA was prevalent but unrecognized over a 40-year time horizon. Patients were assumed to be routinely seen at a dermatology clinic.

Background Biologics effectively improve psoriatic skin lesions, but their impact on itch relief remains unclear.Objective To evaluate itch improvement in severe psoriasis patients treated with ustekinumab or guselkumab.Methods This retrospective study analyzed patients with severe psoriasis who completed initial efficacy evaluations after treatment with either biologic. Itch severity was assessed using numerical rating scale (NRS), visual analog scale, and verbal rating scale. NRS improvement w

Background Nail psoriasis (NP) is not an uncommon psoriasis variant whose symptoms have a negative impact on patients' quality of life. Treating NP can be a great challenge for the dermatologist, especially when it is presented as isolated subtype or when it is not associated with psoriatic arthritis (PsA). The available treatments, topical or systemic therapies, have limited efficacy and can be associated with adverse effects (AEs). Topical roflumilast is an FDA-approved treatment for skin plaq

Objectives To test the hypothesis that recently-developed total body-positron emission tomography (TB-PET) imaging with integrated computed tomography (CT) will enable low-dose, quantitative, domain-specific evaluation of the total inflammatory burden of psoriatic arthritis (PsA) and associate with established outcome measures of the clinical domains of PsA.Methods Seventy-one adult participants (40 with PsA, 16 with rheumatoid arthritis (RA), and 15 with osteoarthritis (OA)) underwent 20-min TB

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is more prevalent in patients with psoriasis compared to healthy individuals. Interleukin (IL)-17 and IL-23 inhibitors may have beneficial effects on MASLD by reducing systemic inflammation and improving metabolic parameters.Objectives To assess the effect of IL-17 and IL-23 inhibitors on MASLD and liver fibrosis in patients with psoriasis.Design We performed a systematic review that followed the Preferred Reporting Item

Objective.— To analyze a published study on all-cause mortality between psoriatic arthritis and matched population comparator-subjects to derive comparative mortality statistics applicable to life insurance underwriting.Method.— The pixel method was employed for extracting cumulative survivals. It was chosen for its capability to extract data from published graphs despite potential precision and reliability limitations.Results.— The mortality analysis indicated an increase in mortality starting

The correlation between psoriasis with individual cardiometabolic diseases (CMDs), including coronary heart disease (CHD), stroke, hypertension, heart failure (HF), and type 2 diabetes mellitus (T2DM), have yielded conflicting results, and genetic susceptibility's role in modifying these relationships remains unexplored. To investigate the association of psoriasis with the risk of CMDs, and to assess the modified effect of genetic susceptibility on these associations. A total of 390,165 particip

Objectives To explore the extent to which skin severity is reflected in the Psoriatic Arthritis Disease Activity Score (PASDAS).Methods Cross-sectional baseline data from the British Society for Rheumatology PsA register (BSR-PsA) and the GRAPPA Composite Exercise (GRACE) dataset was included. The body surface area score (BSA) and the Dermatology Life Quality Index (DLQI) were used to assess skin disease activity. BSA was categorized as none (0%), mild (<3%), moderate (3-10%) and severe (>

Psoriasis is a prevalent inflammatory skin disorder with immune-related mechanisms that remain incompletely understood. To elucidate the immune landscape of psoriasis, we analyzed expression profiles to identify 115 psoriasis susceptibility genes (PSGs) and subsequently pinpointing eight immune-related hub genes (IRHGs). A predictive model incorporating these IRHGs demonstrated promising prognostic potential for psoriasis. Additionally, extensive intercellular communication was observed among ke

Background Although the data on psoriasis epidemiology included in the Global Psoriasis Atlas (GPA) provide valuable information on psoriasis prevalence worldwide, the GPA database is still incomplete. Therefore, the aim of the study was to assess the prevalence, incidence, and mortality rates of psoriasis and its types in Poland based on the data registered by the National Health Fund (NHF).Methods The study included psoriasis patients registered at least twice in the Polish NHF database betwee

Background Psoriasis is a systemic immune disease associated with the development of various cancers. However, the causal nature of this association remains unclear. This study aims to systematically investigate the potential causal relationship between psoriasis and 32 types of cancer.Methods We utilized data from two large genomic databases, the UK Biobank and FinnGen, to extract GWAS summary statistics for 32 cancer types as outcomes and psoriasis-related data as exposures. Mendelian randomiz

Background In recent years, the prevalence of uveitis among patients with psoriasis has shown a noticeable upward trend. Previous studies have investigated the immunological mechanisms underlying the potential connection between psoriasis and uveitis, but systematic studies exploring their bidirectional relationship is absent. This study aims to systematically evaluate the bidirectional association between psoriasis and uveitis to provide evidence.Methods We thoroughly searched PubMed, Embase, a

Background Psoriatic Arthritis (PsA), an immune mediated inflammatory arthritis, affects a quarter of patients with cutaneous psoriasis, usually after psoriasis onset. Early diagnosis of PsA is challenging. A biomarker-based diagnostic test may facilitate early diagnosis.Objectives We aimed to determine whether specific clinical features or genetic and protein markers, alone or in combination, can distinguish patients with PsA from those with psoriasis without PsA (PsC).Methods Patients with PsA

Background Psoriasis skin lesions are generally thought to occur before psoriatic arthritis (PsA) develops. However, PsA may be challenging to diagnose in the absence of psoriasis and might be underdiagnosed when occurring before psoriasis. We tested the hypothesis that PsA may commonly occur before psoriasis, but without psoriasis skin lesions, is diagnosed as another form of arthritis.Methods A single-center retrospective chart review was performed to identify patients with qualifying diagnose

Introduction SB17 is a ustekinumab (UST) biosimilar targeting interleukin-12/23 for treating immune-mediated inflammatory diseases (IMIDs). The development of UST biosimilars like SB17 may help address the high cost of innovator biologics, offering affordable alternatives without compromising efficacy or safety.Areas covered This review encompasses the totality of evidence supporting SB17's similarity to UST, its regulatory approval, and indication extrapolation. It also discusses SB17's lower i

Psoriasis is an immune-mediated chronic inflammatory disease. Increasing evidence suggests a close association between ribosome biogenesis (RiboSis) and the pathogenesis of psoriasis. However, the precise mechanisms remain unclear. We first obtained bulk transcriptome and single-cell RNA sequencing datasets from the GEO database. Subsequently, differential expression analysis (DEG) and weighted gene co-expression network analysis (WGCNA) were performed, preliminarily identifying 11 candidate bio

Background Psoriasis and psoriatic arthritis are chronic autoimmune inflammatory conditions frequently associated with a range of comorbidities, including oncological diseases. Managing these conditions in patients with a history of cancer requires careful consideration of treatment efficacy and safety. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, has shown promise in the treatment of psoriasis and psoriatic arthritis. However, data on its use in oncological patients remain limited.

To describe the design and methodology of APACHE, a cohort of patients with early peripheral psoriatic arthritis (pPsA), and to assess the main baseline clinical characteristics of the first included patients. APACHE is an ongoing prospective multicentre national cohort (NCT03768271) with a planned follow-up of 10 years. Included patients have recent-onset (<12 months) peripheral arthritis, a personal and/or family history of psoriasis, pPsA diagnosed by a rheumatologist, and no history of ta

Psoriasis pathogenesis involves dysregulated immune responses, yet the role of protein prenylation (particularly PGGT1B-mediated geranylgeranylation) in macrophage-driven inflammation remains poorly understood. This study aims to explore the role and molecular mechanism of protein geranylgeranyltransferase type I subunit beta (PGGT1B) in the development of psoriasis. Myeloid cell-specific PGGT1B gene knockout mice were generated, and a mouse psoriasis model was established with imiquimod to stud

Abstract Objective: We aimed to identify and characterize distinct subgroups of patients with psoriatic arthritis (PsA) based on their responses to the Assessment of SpondyloArthritis International Society Health Index (ASAS HI), using latent class analysis (LCA). Methods: We performed a latent class analysis on 17 dichotomous ASAS HI items in a cohort of patients with PsA (n: 90). A Gaussian mixture model was applied, and the optimal number of classes was selected based on the Akaike (AIC) and

Justification and objectives: Topical therapy is vital in the management of psoriasis. In recent years there have been multiple advances and changes in the management of psoriatic patients that justify a review and update of the use of topical therapy. Experts from the Spanish Psoriasis Working Group (GPS) of the Spanish Academy of Dermatology Venereology (AEDV) have developed a set of recommendations for the treatment of psoriasis based on the best available evidence and experts' opinion. Metho

Psoriasis is a significant global health challenge due to limited treatment efficacy. Paris saponin VII (PSVII) shows anti-inflammatory and anti-proliferative potential but its role in psoriasis is unclear. In this study, PSVII was identified from a library of natural compounds as a therapeutic candidate for psoriasis. In a murine model, PSVII reduced skin lesion severity, epidermal thickness, and inflammatory factor expression, preliminaryly indicating its anti-inflammatory properties. In vitro

Background Psoriasis is a chronic inflammatory skin condition driven by immune dysregulation, significantly diminishing patients' quality of life. The advent of targeted biological therapies and small molecule inhibitors has transformed the treatment landscape for moderate-to-severe Psoriasis. Nevertheless, there remains a scarcity of comparative efficacy and safety data between these therapeutic classes, highlighting the need for a systematic review to evaluate their relative performance.Object

The Psoriasis Area and Severity Index (PASI) is widely used to evaluate psoriatic disease activity in clinical settings; however, its limitations hinder its practicality in routine use. The Simple-Measure for Assessing Psoriasis Severity (S-MAPA) has emerged as a promising tool addressing these limitations, providing a more feasible approach for assessing disease severity. This study aimed to evaluate the S-MAPA as a sensitive and practical alternative to existing instruments for measuring psori

No abstract supplied.Weiterlesen